It was surprising last week to learn Harbour Asset Management had increased its shareholding in beleaguered cancer diagnostic company Pacific Edge to 14.5% from 13.48%.
To use a boxing analogy, the dual-listed Pacific Edge is still reeling from a heavy blow, that its Cxbladder tests will no longer
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
